Published in Nat Rev Immunol on September 01, 2008
Mesenchymal Stem Cell Therapy for Liver Cirrhosis | NCT03626090
Allogeneic MSC Treatment for Pulmonary Emphysema | NCT04918706
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell (2009) 7.62
Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 4.75
Organization of immunological memory by bone marrow stroma. Nat Rev Immunol (2010) 3.57
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One (2010) 3.14
Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell (2012) 2.87
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One (2012) 2.75
Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U S A (2010) 2.74
A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest (2013) 2.71
Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng (2010) 2.66
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med (2013) 2.60
Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med (2009) 2.60
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells (2010) 2.54
Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One (2010) 2.38
Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol (2011) 2.38
Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol (2009) 2.37
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol (2011) 2.31
Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A (2010) 2.27
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med (2010) 2.22
Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol (2011) 2.18
Immunobiology of mesenchymal stem cells. Cell Death Differ (2013) 2.18
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin (2013) 2.10
The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A (2009) 2.07
Granulomas of intestinal tuberculosis and Crohn's disease can be differentiated by CD73 cell surface marker expression: a pilot study. Dig Dis Sci (2013) 2.05
Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 2.01
Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells (2010) 1.98
CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell (2012) 1.97
Intra-articular injection of human mesenchymal stem cells (MSCs) promote rat meniscal regeneration by being activated to express Indian hedgehog that enhances expression of type II collagen. Osteoarthritis Cartilage (2012) 1.96
Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. Disaster Med Public Health Prep (2011) 1.93
How mesenchymal stem cells interact with tissue immune responses. Trends Immunol (2012) 1.92
IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One (2010) 1.92
Mesenchymal stem cells prevent hypertrophic scar formation via inflammatory regulation when undergoing apoptosis. J Invest Dermatol (2014) 1.90
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol (2010) 1.82
Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med (2011) 1.72
Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes (2010) 1.69
Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci U S A (2012) 1.68
Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc (2011) 1.66
Adipose-derived stromal cells: Their identity and uses in clinical trials, an update. World J Stem Cells (2011) 1.61
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci U S A (2011) 1.58
Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest (2010) 1.54
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation (2013) 1.53
MSC Transplantation Improves Osteopenia via Epigenetic Regulation of Notch Signaling in Lupus. Cell Metab (2015) 1.49
Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther (2011) 1.49
Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One (2013) 1.48
Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Mol Ther (2010) 1.47
Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS (2013) 1.45
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med (2012) 1.44
Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/β-catenin signaling. Stem Cells Dev (2010) 1.44
Systemically delivered insulin-like growth factor-I enhances mesenchymal stem cell-dependent fracture healing. Growth Factors (2012) 1.42
Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy (2010) 1.41
The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc (2013) 1.40
Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease. Stem Cell Res Ther (2015) 1.40
Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther (2010) 1.39
Therapeutic Potential of Olfactory Ensheathing Cells and Mesenchymal Stem Cells in Spinal Cord Injuries. Stem Cells Int (2017) 1.39
Risk factors in the development of stem cell therapy. J Transl Med (2011) 1.38
Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol (2010) 1.36
Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy (2009) 1.35
Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-α. Nat Protoc (2012) 1.34
Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem (2012) 1.33
Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol Gastrointest Liver Physiol (2011) 1.33
Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med (2012) 1.32
Sonic Hedgehog influences the balance of osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Tissue Eng Part A (2010) 1.32
Participation of blood vessel cells in human adaptive immune responses. Trends Immunol (2011) 1.30
SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β-catenin. EMBO Mol Med (2013) 1.30
Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease. Stem Cells (2011) 1.29
Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells (2014) 1.29
Bone substitutes in orthopaedic surgery: from basic science to clinical practice. J Mater Sci Mater Med (2014) 1.27
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 1.26
Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells (2012) 1.26
New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther (2010) 1.24
Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol (2009) 1.23
Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J Mol Med (Berl) (2009) 1.22
Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One (2009) 1.21
EF1alpha and RPL13a represent normalization genes suitable for RT-qPCR analysis of bone marrow derived mesenchymal stem cells. BMC Mol Biol (2010) 1.21
Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood (2012) 1.20
Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide. PLoS One (2011) 1.20
Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells Int (2012) 1.20
Immunological applications of stem cells in type 1 diabetes. Endocr Rev (2011) 1.20
Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther (2012) 1.19
Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther (2010) 1.18
Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am J Cancer Res (2011) 1.18
Radiation rescue: mesenchymal stromal cells protect from lethal irradiation. PLoS One (2011) 1.17
Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer (2010) 1.17
Acute graft-versus-host disease: new treatment strategies. Curr Opin Hematol (2009) 1.16
Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. Dis Model Mech (2009) 1.16
Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol (2014) 1.15
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. Front Oncol (2015) 1.15
Bone-marrow-derived mesenchymal stem cells for organ repair. Stem Cells Int (2013) 1.14
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med (2012) 2.58
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One (2008) 2.51
Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol (2007) 2.50
Immunoregulatory function of mesenchymal stem cells. Eur J Immunol (2006) 2.47
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
What is a natural killer cell? Nat Immunol (2002) 2.11
NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol (2002) 2.02
TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood (2003) 2.01
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells (2007) 1.94
A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood (2012) 1.92
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A (2004) 1.91
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
Cellular ligands of activating NK receptors. Trends Immunol (2005) 1.84
The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure (2003) 1.82
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78
Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2010) 1.74
Retracted The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest (2004) 1.68
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood (2010) 1.67
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 1.66
Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol (2007) 1.62
The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol (2003) 1.60
Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood (2005) 1.57
Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood (2011) 1.56
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res (2012) 1.55
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol (2003) 1.55
Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol (2004) 1.53
The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol (2004) 1.50
Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood (2002) 1.49
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev (2008) 1.47
NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol (2009) 1.46
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells (2008) 1.42
Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol (2005) 1.42
The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood (2006) 1.41
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res (2009) 1.41
Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci U S A (2002) 1.40
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol (2009) 1.37
Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood (2005) 1.37
Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol (2008) 1.36
Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther (2007) 1.35
Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol (2005) 1.35
IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol (2003) 1.35
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.34
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells (2007) 1.31
Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci U S A (2010) 1.30
Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (2008) 1.28
The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci U S A (2010) 1.28
HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A (2003) 1.27
The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood (2005) 1.26
Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat Immunol (2006) 1.23
Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells (2009) 1.22
Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 1.22
Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood (2008) 1.22
Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood (2011) 1.22
Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. Int Immunol (2008) 1.20
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol (2011) 1.19
The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res (2006) 1.18
Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res (2007) 1.18
Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol (2011) 1.18
Mechanisms of immune evasion of human neuroblastoma. Cancer Lett (2005) 1.17
Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol (2012) 1.16
The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol (2005) 1.15
Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur J Immunol (2008) 1.15
Analysis of natural killer cells isolated from human decidua: Evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood (2006) 1.14
Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene (2005) 1.13
A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood (2005) 1.12
Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol (2011) 1.12
Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood. J Immunol (2014) 1.12
Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol (2005) 1.12
Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood (2006) 1.11
IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol (2005) 1.11
PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol (2005) 1.11
Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol (2013) 1.10
CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci U S A (2011) 1.09
Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. Eur J Immunol (2003) 1.08
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol (2005) 1.08